Advertisement

Comparative Clinical Pathology

, Volume 27, Issue 3, pp 755–764 | Cite as

Potential pharmaceutic effect of Shilajit (mumie) on experimental osteoarthritis in rat

  • Shahrzad Azizi
  • Reza Kheirandiah
  • Omid Azari
  • Nafise Torabi
Original Article
  • 56 Downloads

Abstract

Osteoarthritis (OA) is a worldwide joint disease with clinically loss of motion and pain in human. The conventional treatments are associated with essential side effects. In folk medicine, Shilajit is applied for treatment of arthritis and bone fractures. The present study evaluated effect of Shilajit on the osteoarthritis in rat model. Thirty-six adult male rats were randomly divided into two groups including OA and treated with Shilajit groups. OA was induced by injection of monosodium iodoacetate in the articular space of femorotibial joint. Aqueous extract of Shilajit was given to the treatment group by gavage as daily during experimental course until 21 days. The joint samples were investigated 7, 14, and 21 days post induction. The main macroscopic changes in the affected joints were swelling and congestion at early stages. Histopathologic study showed surface irregularity, erosion and fissures, necrotic chondrocytes, depletion of toluidine blue staining, and lysis of subchondral bone in both OA and Shilajit groups after 7 and 14 days. Synovium revealed synovial cells hyperplasia and inflammatory cells infiltration. Moderate to advanced OA was seen in both groups without significant difference. After 21 days, histopathologic scores of destructive damages and synovitis were reduced in the Shilajit group and showed significant difference in compare to OA group. The present study shows that aqueous extract of Shilajit decreased cartilage degenerative changes in knee osteoarthritis. Also, it reduced inflammatory reactions in synovial membrane.

Keywords

Osteoarthritis Monosodium iodoacetate Shilajit Toluidine blue Pathology 

Notes

Acknowledgements

We would like to thank from Mr. Saeed Hassanzadeh for providing tissue sections.

Funding information

This study was funded by grant number (AZ-91-11).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All animals received human care in compliance with the Guide for Care and use of Laboratory. Animals published by the National Institutes of Health (NIH publication No. 85-23, revised 1985). The study was approved by the local ethics committee of our veterinary school.

References

  1. Abshenas J, Kheirandish R, Salary AR (2014) Gastroprotective effect of mummy on induced gastric ulcer in rats. Comp Clin Pathol 23(2):305–309CrossRefGoogle Scholar
  2. Acharya SB, Frotan MH, Goel RK, Tripathi SK, Das PK (1988) Pharmacological actions of Shilajit. Indian J Exp Biol 26:775–777PubMedGoogle Scholar
  3. Adatia A, Rainsford KD, Kean WF (2012) Osteoarthritis of the knee and hip. Part I: aetiology and pathogenesis as a basis for pharmacotherapy. J Pharm Pharmacol 64(5):617–625CrossRefPubMedGoogle Scholar
  4. Aeschbacher M, Graf C, Schwarzenbach RP, Sander M (2012) Antioxidant properties of humic substances. Environ Sci Technol 46(9):4916–4925CrossRefPubMedGoogle Scholar
  5. Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK (2007) Shilajit: a review. Phytother Res 21:401–405CrossRefPubMedGoogle Scholar
  6. Bhattacharya SK, Sen A (1995) Effects of Shilajit on biogenic free radicals. Phytother Res 9:56–59CrossRefGoogle Scholar
  7. Carrasco-Gallardo C, Farıas GA, Fuentes P, Crespo F, Maccionia RB (2012) Can nutraceuticals prevent Alzheimer’s disease? Potential therapeutic role of a formulation containing Shilajit and complex B vitamins. Arch Med Res 43:699–704CrossRefPubMedGoogle Scholar
  8. Cheng DS, Visco CJ (2012) Pharmaceutical therapy for osteoarthritis. PM R 4:S82–S88CrossRefPubMedGoogle Scholar
  9. Cornejo A, Jimenez JM, Caballero L, Melo F, Maccioni RB (2011) Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease. J Alzheimers Dis 27:143–153PubMedGoogle Scholar
  10. Cournil C, Liagre B, Grosin L, Vol C, Abid A (2001) Overexpression and induction of heat shock protein (Hsp) 70 protects in vitro and in vivo from mono-iodoacetate (MIA)-induced chondrocytes death. Arthritis Res 3(Suppl 1):P41CrossRefPubMedCentralGoogle Scholar
  11. Dehghan M, Sharifi Faradonbeh A (2012) The effect of mummy on the healing of bone fractures. Afr J Pharm Pharmacol 6(5):305–309CrossRefGoogle Scholar
  12. Di Paola R, Cuzzocrea S (2008) Autoimmunity of animal model of arthritis. Autoimmun Rev 8:73–75CrossRefPubMedGoogle Scholar
  13. Franceschi RT, Wilson JX, Dixon SJ (1995) Requirement for Na (+)-dependent ascorbic acid transport in osteoblast function. Am J Phys 268:C1430–C1439CrossRefGoogle Scholar
  14. Frolova LN, Kiseleva TL (1996) Chemical composition of mumie and methods for determination of its authenticity and quality. Chem Pharm J 8:49–53Google Scholar
  15. Gaikwad NS, Panat AV, Deshpande MS, Ramya K, Khalid PU, Augustine P (2012) Effect of shilajit on the heart of Daphnia: a preliminary study. J Ayurveda Integr Med 3(1):3–5CrossRefPubMedPubMedCentralGoogle Scholar
  16. Ghosal S, Lal J, Singh SK, Goel RK, Jaiswal AK, Bhattacharya SK (1991) The need for formulation of Shilajit by its isolated active constituents. Phytother Res 5:211–216CrossRefGoogle Scholar
  17. Ghosal S, Baumik S, Chattopadhyay S (1995) Shilajit induced morphometric and functional changes in mouse peritoneal macrophages. Phytother Res 9:194–198CrossRefGoogle Scholar
  18. Goel RK, Banerjee RS, Acharya SB (1990) Antiulcerogenic and anti-inflammatory studies with Shilajit. J Ethnopharmacol 29:95–103CrossRefPubMedGoogle Scholar
  19. Goldring MB, Otero M (2011) Inflammation in osteoarthritis. Curr Opin Rheumatol 23(5):471–478CrossRefPubMedPubMedCentralGoogle Scholar
  20. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K (2003) Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 31:619–624CrossRefPubMedGoogle Scholar
  21. Hinton R, Moody RL, Davis AW, Thomas SF (2002) Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 65:841–848PubMedGoogle Scholar
  22. Iannone F, Lapadula G (2010) Obesity and inflammation-targets for OA therapy. Curr Drug Targets 11(5):586–598CrossRefPubMedGoogle Scholar
  23. Ismailova VN (1965) To a question about the dosage of mumie and special features of the healing of the fractures of the bones during its application. Med J Uzbekistan 9:69–70Google Scholar
  24. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP (1997) Osteogenic differentiation of purified, culture expanded human mesenchymal stem cells in vitro. J Cell Biochem 64:295–312CrossRefPubMedGoogle Scholar
  25. Joone GK, van Rensburg CEJ (2004) An in vitro investigation of the anti-inflammatory properties of potassium humate. Inflammation 28(3):169–117CrossRefPubMedGoogle Scholar
  26. Junec R, Morrow R, Schoenherr JI, Schubert R, Kallmeyer R, Phull S, Klöcking R (2009) Bimodal effect of humic acids on the LPS-induced TNF-α release from differentiated U937 cells. Phytomedicine 16(5):470–476CrossRefGoogle Scholar
  27. Jung CR, Schepetkin IA, Woo SB, Khlebnikov AI, Kwon BS (2002) Osteoblastic differentiation of mesenchymal stem cells by mumie extract. Drug Develop Res 57:122–133CrossRefGoogle Scholar
  28. Kelginbaev NS, Sorokina VA, Stefanidu AG, Ismailova VN (1973) Treatment of long tubular bone fractures with mumie asil preparations in experiments and clinical conditions. Exp Surg Anesthes 4:31–35Google Scholar
  29. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda M, Fukunari A, Komatsu H (2003) Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats. J Vet Med Sci 65:1195–1199CrossRefPubMedGoogle Scholar
  30. Korago AA. (1992). Introduction in biominerology. Nauka St. Petersburg. p 280Google Scholar
  31. Krenn V, Morawietz L, Häupl T, Neidel J, Petersen I, König A (2002) Grading of chronic synovitis—a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract 198(5):317–325CrossRefPubMedGoogle Scholar
  32. Kučerík J, Bakajová B, Pekař M (2008) Antioxidant effect of lignite humic acids and its salts on the thermo-oxidative stability/degradation of polyvinyl alcohol blends. Environ Chem Lett 6(4):241–245CrossRefGoogle Scholar
  33. Labban NY (2013) Shilajit, a novel regulator of bone/cartilage healing. Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree. Doctor of Philosophy in the School of Dentistry, Indiana UniversityGoogle Scholar
  34. Le Graverand-Gastineau MP (2010) Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets 11:528–535CrossRefPubMedGoogle Scholar
  35. Maccioni RB, Farías GA, Rojo LE, Jiménez JM (2012) In search of therapeutic solutions for Alzheimer’s disease. In: Mantamadiotis T (ed) Brain WTGW-DaDotH, pp 125–150Google Scholar
  36. Mankin HJ, Dorfman H, Lippiello L, Zarins A (1971) Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg 53(3):523–537CrossRefPubMedGoogle Scholar
  37. Naveen SV, Ahmad RE, Hui WJ, Suhaeb AM, Murali MR, Shanmugam R, Kamarul T (2014) Histology, glycosaminoglycan level and cartilage stiffness in monoiodoacetate-induced osteoarthritis: comparative analysis with anterior cruciate ligament transection in rat model and human osteoarthritis. Int J Med Sci 11(1):97–105CrossRefPubMedGoogle Scholar
  38. Neogi T (2013) The epidemiology and impact of pain in osteoarthritis. Osteoarthr Cartil 21(9):1145–1153CrossRefPubMedPubMedCentralGoogle Scholar
  39. Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A (2011) Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Exp Rev Clin Pharm 4:605–621CrossRefGoogle Scholar
  40. Qutob S, Dixon SJ, Wilson JX (1998) Insulin stimulates vitamin C recycling and ascorbate accumulation in osteoblastic cells. Endocrinol 139:51–56CrossRefGoogle Scholar
  41. Rege AAA, Chowdhary AS (2014) Evaluation of Shilajit as putative HIV-protease inhibitor. Intern J Adv Res 2:154–157Google Scholar
  42. Rosenberg A (2002) Bones, joints, soft tissue tumors. In: Cotran R, Kuman V, Collins T (eds) Pathologic basis of disease. WB Saunders, Philadelphia, pp 1215–1268Google Scholar
  43. Schepetkin I, Khlebnikov A, Kwon BS (2002) Medical drugs from humus matter: focus on mumie. Drug Dev Res 57:140–159CrossRefGoogle Scholar
  44. Schepetkin IA, Khlebnikov AI, Ah SY, Woo SB, Jeong CS, Klubachuk ON, Kwon BS (2003) Characterization and biological activities of humic substances from mumie. J Agric Food Chem 51(18):5245–5254CrossRefPubMedGoogle Scholar
  45. Tripathi YB, Shukla S, Chaurasia S (1996) Antilipid peroxidative property of Shilajit. Phytother Res 10:269–270CrossRefGoogle Scholar
  46. van Rensburg CE, Naude PJ (2009) Potassium humate inhibits the production of inflammatory cytokines and complement activation in vitro. Inflammation 32(4):270–276CrossRefPubMedGoogle Scholar
  47. Vašková J, Veliká B, Pilátová M, Kron I, Vaško L, Vaško L (2011) Effects of humic acid in vitro. In Vitro Cell Dev Biol Anim 47:376–382CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathobiology, Faculty of Veterinary MedicineShahid Bahonar University of KermanKermanIran
  2. 2.Department of Clinical Sciences, Faculty of Veterinary MedicineShahid Bahonar University of KermanKermanIran
  3. 3.Graduated Student, Faculty of Veterinary MedicineShahid Bahonar University of KermanKermanIran

Personalised recommendations